Antibiotice lasi announced earnings results for the nine months of 2017. For the nine months, the company’s sales revenues amounted to RON 234.2 million, by 4% higher than the estimate indicated in the Income and Expenditure Budget, and by 3% higher compared to the similar period of 2016, when the sales revenues amounted RON 227.3 million. Moreover, the net profit amounted to RON 20.24 million, by 37% higher than the value indicated in the Budget and by 14% higher than in the first nine months of 2016.